Cancer and sepsis.
暂无分享,去创建一个
[1] J. Bjørnholt,et al. Clinical outcomes of antimicrobial resistance in cancer patients: a systematic review of multivariable models , 2023, BMC Infectious Diseases.
[2] F. Barlesi,et al. Anti-TIGIT therapies for solid tumors: a systematic review , 2023, ESMO open.
[3] Teng Zhang,et al. Role of regulation of PD-1 and PD-L1 expression in sepsis , 2023, Frontiers in Immunology.
[4] Guo-rui Sun,et al. A clinically applicable prediction model for the risk of in-hospital mortality in solid cancer patients admitted to intensive care units with sepsis , 2023, Journal of Cancer Research and Clinical Oncology.
[5] S. Chawla,et al. Delirium as a Risk Factor for Mortality in Critically Ill Patients With Cancer , 2023, JCO oncology practice.
[6] Elizabeth L Siegler,et al. CAR-T Cell Therapy: the Efficacy and Toxicity Balance , 2023, Current Hematologic Malignancy Reports.
[7] S. Dutta,et al. Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors , 2023, Biology.
[8] S. Jhanji,et al. Management of adult patients with haematological malignancies in critical care , 2023, Anaesthesia.
[9] H. Gershengorn,et al. The Sequential Organ Failure Assessment (SOFA) Score: has the time come for an update? , 2023, Critical Care.
[10] A. Jemal,et al. Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.
[11] Jianpeng Sheng,et al. TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies , 2022, Frontiers in Oncology.
[12] Yurii B. Shvetsov,et al. Transcriptome profiling of colorectal tumors from patients with sepsis reveals an ethnic basis for viral infection risk and sepsis progression , 2022, Scientific Reports.
[13] C. Tong,et al. Role of CD8+ T cell exhaustion in the progression and prognosis of acute respiratory distress syndrome induced by sepsis: a prospective observational study , 2022, BMC Emergency Medicine.
[14] K. Bowles,et al. Why Sepsis Survivors Need an ICD-10 Code for "Sepsis Aftercare". , 2022, Chest.
[15] Katrina L Kalantar,et al. Integrated host-microbe plasma metagenomics for sepsis diagnosis in a prospective cohort of critically ill adults , 2022, Nature Microbiology.
[16] J. Nates,et al. All-cause mortality in cancer patients treated for sepsis in intensive care units: a systematic review and meta-analysis , 2022, Supportive Care in Cancer.
[17] M. Churpek,et al. Development and validation of novel sepsis subphenotypes using trajectories of vital signs , 2022, Intensive Care Medicine.
[18] J. Hodge,et al. Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation , 2022, Frontiers in Immunology.
[19] Songqiao Liu,et al. Expression of PD-1 on Memory T Lymphocytes Predicts 28-Day Mortality of Patients with Sepsis: A Prospective Observational Study , 2022, Journal of inflammation research.
[20] Yuko Ono,et al. Prevalence and Long-Term Prognosis of Post-Intensive Care Syndrome after Sepsis: A Single-Center Prospective Observational Study , 2022, Journal of clinical medicine.
[21] J. Mascarenhas,et al. Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients. , 2022, Clinical lymphoma, myeloma & leukemia.
[22] Meiling Xiang,et al. Impact of cancer on mortality rates in patients with sepsis: A meta-analysis and meta-regression of current studies , 2022, World journal of clinical cases.
[23] M. Singer,et al. Redefining critical illness , 2022, Nature Medicine.
[24] C. Sprung,et al. Outcomes and predictors of 28-day mortality in patients with solid tumors and septic shock defined by Sepsis-3 criteria. , 2022, Chest.
[25] Yumin Li,et al. Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy , 2022, Frontiers in Oncology.
[26] F. Moreno-Sánchez,et al. Antibiotic Management of Patients with Hematologic Malignancies: From Prophylaxis to Unusual Infections , 2022, Current Oncology Reports.
[27] V. Notario,et al. The Interplay among Radiation Therapy, Antibiotics and the Microbiota: Impact on Cancer Treatment Outcomes , 2022, Antibiotics.
[28] Li Li,et al. Risk of Adverse Financial Events in Patients With Cancer: Evidence From a Novel Linkage Between Cancer Registry and Credit Records , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] D. Schadendorf,et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. , 2022, The New England journal of medicine.
[30] Xiaochun Ma,et al. Immune checkpoint molecule TIGIT manipulates T cell dysfunction in septic patients. , 2021, International immunopharmacology.
[31] C. Sprung,et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. , 2021, Critical care medicine.
[32] V. Fowler,et al. Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward , 2021, CA: a cancer journal for clinicians.
[33] A. Soubani,et al. Sepsis Hospitalizations With Versus Without Cancer , 2021, American journal of clinical oncology.
[34] C. Coopersmith,et al. TIGIT modulates sepsis-induced immune dysregulation in mice with preexisting malignancy , 2021, JCI insight.
[35] C. Coopersmith,et al. Tumor-Specific T Cells Exacerbate Mortality and Immune Dysregulation during Sepsis , 2021, The Journal of Immunology.
[36] J. Carratalá,et al. Understanding and Managing Sepsis in Patients With Cancer in the Era of Antimicrobial Resistance , 2021, Frontiers in Medicine.
[37] R. Korn,et al. Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors , 2020, Clinical Cancer Research.
[38] L. Chambers,et al. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer. , 2020, Gynecologic oncology.
[39] J. Chiche,et al. Sepsis and Cancer, An Interplay of Friends and Foes. , 2020, American journal of respiratory and critical care medicine.
[40] H. Gerlach,et al. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019— results from a systematic review and meta-analysis , 2020, Critical Care.
[41] É. Azoulay,et al. Sepsis and Septic Shock in Patients With Malignancies: A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique Study* , 2020, Critical care medicine.
[42] T. Buchman,et al. Sepsis Among Medicare Beneficiaries: 1. The Burdens of Sepsis, 2012–2018* , 2020, Critical care medicine.
[43] C. Coopersmith,et al. Preexisting malignancy abrogates the beneficial effects of CXCR4 blockade during sepsis , 2020, Journal of leukocyte biology.
[44] Niranjan Kissoon,et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study , 2020, The Lancet.
[45] Guangyong Peng,et al. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment , 2019, Cellular & Molecular Immunology.
[46] J. Vincent,et al. Which Multicenter Randomized Controlled Trials in Critical Care Medicine Have Shown Reduced Mortality? A Systematic Review. , 2019, Critical care medicine.
[47] C. Coopersmith,et al. 2B4 but not PD-1 blockade improves mortality in septic animals with preexisting malignancy. , 2019, JCI insight.
[48] James R. Brown,et al. T Cell– and Monocyte-Specific RNA-Sequencing Analysis in Septic and Nonseptic Critically Ill Patients and in Patients with Cancer , 2019, The Journal of Immunology.
[49] C. Coopersmith,et al. Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab , 2019, Intensive Care Medicine.
[50] J. Donnelly,et al. Epidemiology and Outcomes of Cancer-Related Versus Non-Cancer-Related Sepsis Hospitalizations. , 2019, Critical care medicine.
[51] K. Carey,et al. Identifying Novel Sepsis Subphenotypes Using Temperature Trajectories. , 2019, American journal of respiratory and critical care medicine.
[52] J. Chiche,et al. Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced Natural Killer cell activity , 2019, Oncoimmunology.
[53] O. Nishida,et al. Pharmacokinetics, Pharmacodynamics, and Safety of Nivolumab in Patients With Sepsis-Induced Immunosuppression: A Multicenter, Open-Label Phase 1/2 Study , 2019, Shock.
[54] C. Coopersmith,et al. Murine Pancreatic Cancer Alters T Cell Activation and Apoptosis and Worsens Survival After Cecal Ligation and Puncture , 2019, Shock.
[55] Jeremy C. Weiss,et al. Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis. , 2019, JAMA.
[56] C. Coopersmith,et al. Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)* , 2019, Critical care medicine.
[57] V. Badovinac,et al. Cutting Edge: Polymicrobial Sepsis Has the Capacity to Reinvigorate Tumor-Infiltrating CD8 T Cells and Prolong Host Survival , 2019, The Journal of Immunology.
[58] S. Lemeshow,et al. Mortality Changes Associated with Mandated Public Reporting for Sepsis. The Results of the New York State Initiative , 2018, American journal of respiratory and critical care medicine.
[59] Zena Werb,et al. Roles of the immune system in cancer: from tumor initiation to metastatic progression , 2018, Genes & development.
[60] E. Engels,et al. Sepsis and Risk of Cancer Among Elderly Adults in the United States , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[61] C. Coopersmith,et al. Pre-existing malignancy results in increased prevalence of distinct populations of CD4+ T cells during sepsis , 2018, PloS one.
[62] C. Coopersmith,et al. CXCR4 blockade decreases CD4+ T cell exhaustion and improves survival in a murine model of polymicrobial sepsis , 2017, PloS one.
[63] Susan Gruber,et al. Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014 , 2017, JAMA.
[64] Peter Nürnberg,et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. , 2017, The Lancet. Respiratory medicine.
[65] C. Coopersmith,et al. Cutting Edge: 2B4-Mediated Coinhibition of CD4+ T Cells Underlies Mortality in Experimental Sepsis , 2017, The Journal of Immunology.
[66] Niranjan Kissoon,et al. Recognizing Sepsis as a Global Health Priority - A WHO Resolution. , 2017, The New England journal of medicine.
[67] S. Lemeshow,et al. Time to Treatment and Mortality during Mandated Emergency Care for Sepsis , 2017, The New England journal of medicine.
[68] Anna Rautanen,et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study , 2016, The Lancet. Respiratory medicine.
[69] C. Coopersmith,et al. Murine Lung Cancer Increases CD4+ T Cell Apoptosis and Decreases Gut Proliferative Capacity in Sepsis , 2016, PloS one.
[70] R. Bellomo,et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.
[71] C. Lindsell,et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. , 2015, American journal of respiratory and critical care medicine.
[72] H. Eguchi,et al. Claudin 2 deficiency reduces bile flow and increases susceptibility to cholesterol gallstone disease in mice. , 2014, Gastroenterology.
[73] Robert S. Benjamin,et al. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses , 2014, Science Translational Medicine.
[74] R. Hotchkiss,et al. Parallels between cancer and infectious disease. , 2014, New England Journal of Medicine.
[75] S. Deweerdt. Bacteriology: A caring culture , 2013, Nature.
[76] T. Lisboa,et al. Critically ill patients with cancer and sepsis: clinical course and prognostic factors. , 2012, Journal of critical care.
[77] C. Coopersmith,et al. Prevention of Lymphocyte Apoptosis in Septic Mice with Cancer Increases Mortality , 2011, The Journal of Immunology.
[78] R. Hotchkiss,et al. Dose-Dependent Effect of Anti-CTLA-4 on Survival in Sepsis , 2011, Shock.
[79] B. Allaouchiche,et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients , 2011, Critical care.
[80] V. Keshamouni,et al. The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth. , 2010, Blood.
[81] C. Coopersmith,et al. Cancer causes increased mortality and is associated with altered apoptosis in murine sepsis* , 2010, Critical care medicine.
[82] C. Chung,et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis , 2009, Proceedings of the National Academy of Sciences.
[83] R. Hotchkiss,et al. BIM siRNA DECREASES LYMPHOCYTE APOPTOSIS AND IMPROVES SURVIVAL IN SEPSIS , 2008, Shock.
[84] D. Mannino,et al. The epidemiology of sepsis in patients with malignancy. , 2006, Chest.
[85] K. Tanabe,et al. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses , 2005, Cancer biology & therapy.
[86] C. Coopersmith,et al. Accelerated Lymphocyte Death in Sepsis Occurs by both the Death Receptor and Mitochondrial Pathways1 , 2005, The Journal of Immunology.
[87] C. Coopersmith,et al. Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. , 2002, JAMA.
[88] C. Coopersmith,et al. Overexpression of Bcl-2 in the intestinal epithelium improves survival in septic mice , 2002, Critical care medicine.
[89] R. Hotchkiss,et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte , 2000, Nature Immunology.
[90] R. Hotchkiss,et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. , 1999, Critical care medicine.
[91] S. Korsmeyer,et al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. , 1999, Journal of immunology.
[92] R. Hotchkiss,et al. Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-cell-deficient mice. , 1997, Critical care medicine.
[93] S. Lemeshow,et al. Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study. , 2015, Critical care medicine.
[94] E. McCarthy. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. , 2006, The Iowa orthopaedic journal.